KARDIOLOGIChESKIY BOL'NOY S ANEMIEY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Anemia in patients with cardiovascular diseases is a serious problem both in terms of detection of pathogenetical link with underlying disease, and the management of these patients. Regardless of whether anemia is a true comorbidity or is associated with the pathogenesis of cardiac pathology, each case requires timely diagnosis of anemia, and verification of pathogenetical variant and the causes for its development, and adequate correction using antianemic drugs, mainly iron supplements.

Full Text

Restricted Access

About the authors

L. I Dvoretskiy

N. V Dyatlov

References

  1. Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006;107(10):3841-46.
  2. Luthi JC, Flanders WD, Burnier M, et al. Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC Nephrol 2006;7:3.
  3. Горохова С.Г., Атаманова М.А, Мурасеева Е.В.Оценка показателей обмена железа у больных с коронарным атеросклерозом и сахарным диабетом 2 типа // Клин. медицина 2007. №11. С. 50-4.
  4. Зюбина Л.Ю., Третьякова С.В., Лосева М.И., Шпагина Л.А. Клиникофункциональная характеристика сердца при железодефицитной анемии // Тер. архив 2002. Т. 74. № 6. С. 66-9.
  5. Cavusoglu E, Chopra V, Gupta A, et al. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. Am J Cardiol 2006;98(5):580-84.
  6. Lipsic E, et al. Hemoglobin levels and 30-day mortality In patients after myocardial infarction. Int.J Card 2005;100(2):289-92.
  7. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-36.
  8. Shu DS, Ransom TP, O'Connell PM, et al. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes Cardiovasc Diabetol 2006;5:89.
  9. Калюта Т.Ю., Токарев В.П., Каримов Р.Н., Шварц Ю.Г. Определение значения анемии в прогнозе рецидива острого инфаркта миокарда // Росс. кардиол. журн. 2006. № 1. С. 58-62.
  10. Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervwntion. Analysis from Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. JACC 2004;44:547-53.
  11. Эрлих АД, Грацианский Н.А. От имени участников регистра РЕКОРД. Особенности лечения и исходы у больных с острым коронарным синдромом и анемией. Результаты регистра РЕКОРД // Росс. кардиол. журн. 2012. № 5. С. 97.
  12. Верткин А.Л., Скотников А.С. Необходимость коррекции дефицита железа у пациентов, длительное время получающих антиагрегантную терапию // Лечащий врач 2012. № 2. С. 20.
  13. Zeidman А, Fradin Z, Blecher A, et al. Anemia as a Risk Factor for Ischemic Heart Disease. IMAJ 2004;6:16-8.
  14. Шилов А.М., Осия А.О. Особенности лечения ишемической болезни сердца на фоне анемии различного генеза // Трудный пациент 2011. № 12.
  15. Белоусова Н.С., Ильина С.А.,Черногорюк Г.Э., Тюкалова Л.И. Влияние коррекции показателей обмена железа и эритрона при железодефицитных анемиях легкой степени на клинические проявления ишемической болезни сердца // Клин. медицина 2012. № 1.С. 13.
  16. Преображенский Д.В., Воробьев П.А., Некрасова Н.И. и др. Анемия у больных с хронической сердечной недостаточностью: распространенность и клиническое значение // Клин. геронтол. 2005. № 10. С. 40-3.
  17. Ryan E, Devlin M, Prendiville T, et al. The Prevalence and Natural History of Anaemia in an Optimally Treated Heart Failure Population. Br J Cardiol 2004;11(5):369-75.
  18. Ezekowitz J, McAlister F, Armstrong P. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with newonset heart failure. Circulation 2003;107(2):223-25.
  19. Nanas J, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Col. Cardiol 2006;48(12):2485-89.
  20. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
  21. Witte K, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004;147:924-30.
  22. Jensen JD, Eiskjaer H, Bagger JP, et al. Elevated level of erythropoietin in congestive heart failure: relationship to renal perfusion and plasma rennin. J Intern Med 1993;233:125-30.
  23. Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 2005;6(Suppl. 3):13-21.
  24. Дятлов Н.В. Хроническая сердечная недостаточность в сочетании с анемическим синдромом: диагностика, лечение и прогноз. Дисс. канд. мед. наук. М., 2011.
  25. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail 2004;10:243-47.
  26. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
  27. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100:2310-14.
  28. Fyhrquist F, Karppinen K, Honkanen T, et al. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989;226:257-60.
  29. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428-34.
  30. Anand IS, Rector T, Deswal A, et al. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 2006;27(Suppl. 1):485.
  31. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-59.
  32. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002;17(Suppl. 11):39-43.
  33. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
  34. Gaetano C, Locati M, Mantovani A. Control of iron homeostasis as a key component of macrophage polarization. Haematologica 2010;95(11):1801-03.
  35. Kannel W. Epidemiology and prevention of car diac failure. Framingham Study insights. Eur Heart J 1987;8(Suppl. F):23-9.
  36. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia Is Associated With Worse Symptoms, Greater Impairment in Functional Capacity and a Significant Increase in Mortality in Patients With Advanced Heart Failure. J Am Coll Cardiol 2002;39:1780-86.
  37. Tang WHW, Tong W, Jain A, et al. Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure. J Am Coll Cardiol 2008;51:569-76.
  38. Kosiborod M, Curtis P, Wang Y, et al. Anemia and Outcomes in Patients With Heart Failure. Arch Intern Med 2005;165:2237-44.
  39. АІ Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38:955-62.
  40. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62.
  41. Anand IS, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110:149-54.
  42. Гончарова Е.В., Говорин А.В., Кузьмин А.Г. и др. Структурно-функциональные показатели миокарда у больных хронической железодефицитной анемией // Кардиология 200. № 48(5). С. 46-50.
  43. Дворецкий Л.И., Желнов В.В., Дятлов Н.В. Эндогенная инотропная стимуляция миокарда у пациентов с хронической сердечной недостаточностью и анемией // Росс. медицинские вести 2012. № 17(2). С. 40-8.
  44. Packer M, Carver J, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325(21):1468-75.
  45. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
  46. Griffing GT, Melby JC. Enalapril (MK-421) and the white cell count and haematocrit. Lancet 1982;1:1361.
  47. Hirakata H, Onoyama K, Iseki K, et al. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984;4:355-60.
  48. Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001;72:542-44.
  49. Wang AY, Yu AW, Lam CW, et al. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis [On-line] 2002;39:600-08.
  50. Glicklich D, Burris L, Urban A, et al. Angiotensinconverting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001;12:1958-64.
  51. Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomized trial. Lancet 2002;359:663-66.
  52. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensinconverting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005;45:391-99.
  53. Cole J, Ertoy D, Lin H, et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000;106:1391-98.
  54. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-44.
  55. Морозова ТЕ, Вартанова ОА. Антиагреганты в лечении ишемической болезни сердца // РМЖ 2012.
  56. Theroux P, Willerson JT, Armstrong PW. Progress in the treatment of acute coronary syndromes: a 50 year perspective. Circulation 2000; 102:IV2-IV13.
  57. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348 (9038):1329-39.
  58. Напалков Д.А. и др. Анемия и хроническая сердечная недостаточность: очевидные факты и нерешенные вопросы. // Врач 2007. № 6. С. 18-22.
  59. Bolger A, Bartlett F, Pension Н, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48(6):1225-27
  60. Мельник М.В. Шилов А.М., Ким И.Р. и др. Хроническая сердечная недостаточность и железодефицитная анемия // Рацион. фармакотерапия в кардиологии 2007. № 1. С. 9-14.
  61. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-65.
  62. Okonko DO, Grzesio A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, con trolled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12.
  63. Anker SD, Colet JC, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009;361:2436-48.
  64. Finch CA, Miller LR, Inamdar AR, et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447-53.
  65. Willis WT, Gohil K, Brooks GA, Dallman PR. Iron deficiency: improved exercise performance within 15 hours of iron treatment in rats. J Nutr 1990;120:909-16.
  66. Ким И.Р. Особенности течения и лечения ишемической болезни сердца при анемии. Дисс. канд. мед. наук. М., 2007.
  67. Carson JL, Adamson JW. Iron Deficiency and Heart Disease: Ironclad Evidence? Hematology 2010;4(1):348-50.
  68. Mancini D, Katz S, Lang C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2);294-99.
  69. Mishra Т, Mishra S, Mohanty N, et al. Prevalence, prognostic importance and therapeutic implications of anemia in heart failure. Indian Heart J 2005;57(6);670-74.
  70. Silverberg D, Wexler D, Blum M, et al. Effects of treatment with epoetin Beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 2005;28(1):41-7.
  71. Усачева Е.И. Качество жизни больных железодефицитными анемиями в оценке эффективности терапии различными препаратами железа. Дисс. канд. мед. наук. СПб., 2002.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies